Department of Oncology, Qujing No.1 Hospital, Qujing, China.
J Clin Pharm Ther. 2022 Aug;47(8):1257-1263. doi: 10.1111/jcpt.13664. Epub 2022 Apr 9.
Camrelizumab is a recently developed PD-1 inhibitor in China applied in treating different cancers including lung cancer. This study is designed to evaluate the efficacy, safety and prognostic factors for camrelizumab plus carboplatin and pemetrexed (CP) chemotherapy in treating patients with advanced lung adenocarcinoma.
Of 51 advanced lung adenocarcinoma patients with negative driver genes who received camrelizumab plus CP chemotherapy were recruited. These patients received four cycles of camrelizumab plus CP chemotherapy in a 21-day cycle. Then, camrelizumab, pemetrexed or camrelizumab plus pemetrexed was administered as maintenance therapy.
The rates of complete response, partial response, stable disease and progressive disease were 2.0%, 56.8%, 19.6% and 5.9%, respectively; while treatment response of 15.7% of patients was missing or not evaluable. The objective response and disease control rates were 58.8% and 78.4%, respectively. With a median follow-up period of 14.9 months (the follow-up duration ranged from 3.9 months to 24.3 months), 41 (83.4%) cases of disease progression and 22 (43.1%) cases of death were recorded. The median progression-free survival (PFS) was 10.5 months (95% confidence interval (CI): 8.4-12.6 months) with a 1-year PFS rate of 36.3% and a 2-year PFS rate of 7.5%. In addition, the median overall survival (OS) was 18.7 months (95% CI: 16.4-21.0 months) with a 1-year OS rate of 79.1% and a 2-year OS rate of 30.4%. In consideration of safety, the most frequent adverse events were peripheral neuropathy (37.3%), neutropenia (37.3%), alopecia (35.3%), etc. and most of them were grade 1-2 and could be controlled.
Camrelizumab plus CP chemotherapy achieves favourable efficacy and tolerable adverse events in advanced lung adenocarcinoma patients.
卡瑞利珠单抗是中国最近开发的一种 PD-1 抑制剂，可用于治疗包括肺癌在内的多种癌症。本研究旨在评估卡瑞利珠单抗联合卡铂和培美曲塞（CP）化疗治疗晚期肺腺癌患者的疗效、安全性和预后因素。
51 例无驱动基因突变的晚期肺腺癌患者接受卡瑞利珠单抗联合 CP 化疗。这些患者在 21 天的周期内接受了四个周期的卡瑞利珠单抗联合 CP 化疗。然后，给予卡瑞利珠单抗、培美曲塞或卡瑞利珠单抗联合培美曲塞作为维持治疗。
完全缓解、部分缓解、疾病稳定和疾病进展的比例分别为 2.0%、56.8%、19.6%和 5.9%；而 15.7%的患者的治疗反应缺失或不可评估。客观缓解率和疾病控制率分别为 58.8%和 78.4%。中位随访期为 14.9 个月（随访时间为 3.9 个月至 24.3 个月），记录到 41 例（83.4%）疾病进展和 22 例（43.1%）死亡。中位无进展生存期（PFS）为 10.5 个月（95%置信区间：8.4-12.6 个月），1 年 PFS 率为 36.3%，2 年 PFS 率为 7.5%。此外，中位总生存期（OS）为 18.7 个月（95%置信区间：16.4-21.0 个月），1 年 OS 率为 79.1%，2 年 OS 率为 30.4%。考虑到安全性，最常见的不良反应是周围神经病变（37.3%）、中性粒细胞减少症（37.3%）、脱发（35.3%）等，大多数为 1-2 级，且可控制。
卡瑞利珠单抗联合 CP 化疗在晚期肺腺癌患者中疗效良好，不良反应可耐受。
